February 2, 2011
Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related to the second Phase 1 clinical trial of SMaRT, which is currently set to begin in the first quarter of 2011 at PRA International’s Lenexa, Kansas, clinical facility.
Image via Wikipedia
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
read more >>